[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623768":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Model G2-TRIO",null,"Subjects receive a Travoprost intracameral implant with the Model G2-TRIO",[13],"Combination Product: Travoprost",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"COMBINATION_PRODUCT","Travoprost","Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Study Director","CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Glaukos Investigative Site","RECRUITING","Kenosha","Wisconsin","53140","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-87.82119,42.58474,{"lat":39,"lon":38},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623768",false,"NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg","TRIO","Inclusion Criteria:\n\n* Diagnosis of Open-angle glaucoma\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Subject who is breast-feeding or pregnant","ALL","18 Years",{"count":53,"type":54},30,"ESTIMATED","OBSERVATIONAL","Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)",[58,59],"Open Angle Glaucoma (OAG)","Ocular Hypertension (OH)",[61,62],"Glaucoma","Ocular Hypertension","2026-02-24",{"date":65,"type":66},"2026-02-27","ACTUAL",{"date":68,"type":66},"2025-12-17",{"date":70,"type":54},"2026-07",{"name":5,"class":6},1]